Shanmugam Anandakumar

Dr. Shanmugam Anandakumar


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Odontology
Verified
Journal Article
Closed access
PDF file
ARAnitha Roy
Anitha Roy
BCBinoy Varghese Cheriyan
Binoy Varghese Cheriyan
EPElumalai Perumal
Elumalai Perumal
Kannan RR RengasamyKannan RR Rengasamy
Kannan RR Rengasamy
SAShanmugam Anandakumar
Shanmugam Anandakumar

10 August 2020 in ChemRxiv
Verified
Preprint
Open access
SAShanmugam Anandakumar
Shanmugam Anandakumar
DKDamodharan Kannan
Damodharan Kannan
EWEugene Wilson
Eugene Wilson
KNKasthuri Bai Narayanan
Kasthuri Bai Narayanan
GSGanesan Suresh
Ganesan Suresh
MMMuthu Tamizh Manoharan
Muthu Tamizh Manoharan
The novel coronavirus is better known as COVID–19 caused by Severe Acute Respiratory Syndrome Corona–Virus 2 (SARS–CoV–2) which initially outburst at Wuhan in China on December 2019 and spread very rapidly around the globe. Scientists from the global regions endeavours to still probe for detecting potential treatment and discover effective therapeutic drug candidates for this unabated pandemic. In our article, we reported the molecular docking, bioactivity score, ADME and toxicity prediction of the phytoconstituents of Solanum trilobatum Linn. such as Solanidine, Solasodine and a –Solanine as potential inhibitors against the main protease (M pro ) of SARS–CoV–2 tropism. The molecular docking of Solanidine, Solasodine and a–Solanine has revealed that it bounded deep into the active cavity site on the M pro . Further, the pharmacodynamics and bioactivity profile has confirmed that the molecules obeyed the Lipinski’s rule and will be used as notably treasured lead drug candidates to pursue further biochemical and cell–based assays to explore its potential against COVID–19 pandemic. Thus, envisioning thought–provoking research certainly provide new leads for the global researchers.


9 January 2024 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
BCBinoy Varghese Cheriyan
Binoy Varghese Cheriyan
PSPunithavel Srinivasan
Punithavel Srinivasan
GPGeorge J Push
George J Push
KKKarthik K K
Karthik K K
PSPrasanna Bharathi Sainath
Prasanna Bharathi Sainath
KEKarthikeyan Elumalai
Karthikeyan Elumalai
The present study aimed to assess the antiproliferative and pro-apoptotic effects of hinokitiol in osteosarcoma cells via in vitro and in silico targeting of glycogen synthase kinase 3β (GSK3β). The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to evaluate the cytotoxic potential of hinokitiol in osteosarcoma cells. Various concentrations of hinokitiol (5, 10, 20, 40, 60, and 80 μg/mL) were tested, and the half-maximal inhibitory concentration (IC50) was calculated. Cell morphology, migration (scratch assay), and gene expression analysis using real-time polymerase chain reaction for pro-apoptotic studies were conducted, with the IC50 dose of hinokitiol utilized in all these experiments. Additionally the anti-proliferative effect of hinokitiol on GSK3β was also examined using in silico and gene expression methods. Hinokitiol significantly (p < 0.05) and dose-dependently decreased the viability of MG-63 cells, with an IC50 value of 40 μg/mL. Cell morphology study revealed cellular shrinkage and reduced cell density. The scratch assay revealed anti-migratory activity, while gene expression studies indicated pro-apoptotic effects, including significant (p < 0.05) upregulation of BAX and down-regulation of BCL-2 and GSK3β. Bonding interactions were also observed with GSK3β and atomic contact energy of -5.69 kcal/mol. According to the current study findings, hinokitiol prevented Morphological study of the effects of hinokitiol on osteosarcoma cells from proliferating, migrating, and induced apoptosis by upregulating BAX (a pro-apoptotic signal) expression and downregulating BCL-2 (anti-apoptotic signal) expression in osteosarcoma cells. In silico findings of hinokitiol showed a significant bonding interaction with GSK3β and its downregulated gene expression probably prevented cancer cell survival.

30 December 2023 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
ASAkkam Sandeep
Akkam Sandeep
KEKarthikeyan Elumalai
Karthikeyan Elumalai
HWHelen Williams
Helen Williams
SSSunilkumar Salkapuram
Sunilkumar Salkapuram
SAShanmugam Anandakumar
Shanmugam Anandakumar
SSSivaneswari Srinivasan
Sivaneswari Srinivasan
Introduction and aim. Anaemia is a chronic kidney disease (CKD) condition characterised by a decline in glomerular filtration rate (GFR) and impaired kidney function. The aim of this study was to assess the prevalence, prescribing patterns, and quality of life of anaemia in patients with chronic renal disease who were adults (>18 years of age) at a tertiary care hospital. Material and methods. Data on demographic characteristics, laboratory results, medication prescriptions, and quality of life assessments were collected. Statistical tests were performed to determine associations between anaemia prevalence and factors like age, gender, and CKD stage. The study included 132 patients, with a gender distribution of 89 men and 43 women. Results. The most frequently prescribed drugs are epoetin (15.06%), multivitamins (14.82%), iron (10.65%), folic acid (10.22%), calcium carbonate (8.17%), calcitriol (5.6%), and omeprazole (4.22%). The cardiovascular system, blood disorders, and blood-producing organs come after the gastrointestinal tract and metabolism in the first anatomical level of the ATC classification. Conclusion. It suggests hospital audits and recommendations for improved prescription practices. Further investigation into anaemia causes and drug class appropriateness is needed, and implementing improvements could potentially improve health outcomes.

12 August 2020 in ChemRxiv
Verified
Preprint
Open access
SAShanmugam Anandakumar
Shanmugam Anandakumar
DKDamodharan Kannan
Damodharan Kannan
EWEugene Wilson
Eugene Wilson
KNKasthuri Bai Narayanan
Kasthuri Bai Narayanan
GSGanesan Suresh
Ganesan Suresh
MMMuthu Tamizh Manoharan
Muthu Tamizh Manoharan
The novel coronavirus is better known as COVID–19 caused by Severe Acute Respiratory Syndrome Corona–Virus 2 (SARS–CoV–2) which initially outburst at Wuhan in China on December 2019 and spread very rapidly around the globe. Scientists from the global regions endeavours to still probe for detecting potential treatment and discover effective therapeutic drug candidates for this unabated pandemic. In our article, we reported the molecular docking, bioactivity score, ADME and toxicity prediction of the phytoconstituents of Solanum trilobatum Linn. such as Solanidine, Solasodine and a–Solanine as potential inhibitors against the main protease (Mpro) of SARS–CoV–2 tropism. The molecular docking of Solanidine, Solasodine and a–Solanine has revealed that it bounded deep into the active cavity site on the Mpro. Further, the pharmacodynamics and bioactivity profile has confirmed that the molecules obeyed the Lipinski’s rule and will be used as notably treasured lead drug candidates to pursue further biochemical and cell–based assays to explore its potential against COVID–19 pandemic. Thus, envisioning thought–provoking research certainly provide new leads for the global researchers.